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Background: The development of intimal hyperplasia s a major cause of early vein graft 
failure. The study examines the effects of locally delivered antisense oligonucleotides to 
the proto-oncogene c-myb on the development of vein graft intimal hyperplasia. 
Methods:" Common carotid vein bypass grafting procedures were performed on 60 New 
Zealand White rabbits. Seventeen grafts were controls, 14 had grafts coated with a 
commercial gel, 17 had grafts coated with gel containing 200 ~g of an antisense c-myb 
oligonucleotide, and 6 rabbits each had grafts coated with gel containing one of two 
control oligonucleotides. Grafts were harvested 28 days after surgery, and sections were 
taken for dimensional nalysis, morphologic evaluation, and vasomotor function. Grafts 
were also harvested at 1 day for oligonucleotide uptake/localization a alysis and at 3 
days for c-myb mRNA analysis. 
Results: Oligonucleotides were uniformly distributed within the media and adventitia by 
1 day. A 38% reduction occurred in mean intimal thickness in the vein grafts coated with 
antisense to c- myb compared with the other groups. No difference in medial thickness was 
seen among groups. By scanning and transmission electron microscopy all vein grafts 
showed a confluent endothelium. In contrast to control vein grafts, which did not relax 
to acetylcholine, most of the gel and all of the gel/oligonucleotide-coated grafts relaxed 
by more than 40% of precontracted tension. Responses to a panel of contractile agents 
were unchanged in the treated groups compared with those in the control group. 
Conclusions: Locally delivered antisense oligonudeotides to proto-oncogene c-myb signif- 
icantly reduces intimal hyperplasia with preservation ofacetylcholine-mediated en othe- 
lium-dependent relaxation in experimental vein grafts. These findings suggest hat 
targeting a common regulatory pathway of vascular smooth muscle mitogenesis can be 
successful in reducing the early development of intimal hyperplasia. (J Vase Surg 1997; 
25:453-63.) 
The universal response to vein bypass grafting is 
the development of intimal hyperplasia in the vessel 
wall.1 This process combines endothelial cell injury, 
dysfunction, or both with smooth muscle cell prolif- 
eration followed by deposition of connective tissue 
matrix and remodeling of  the vascular wall. 2 Vein 
grafts fail early because of development of  intimal 
hyperplasia. The failure rates of vein grafts range 
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from 20% to 40% within 5 years depending on posi- 
tion3-8; however, recent evidence shows that up to 
30% of grafts develop significant stenoses within 18 
months. 911 Histologic examination of these early 
stenoses show intimal hyperplasia, thus making inti- 
mal hyperplasia  major obstacle to improved graft 
patency in this short- to medium-term period) Vein 
grafts in the short and long term have been shown to 
react differently to endothelial cell and smooth mus- 
cle cell vasoactive agonists, leading several authors to 
suggest hat these changes may be markers of the 
particular phenotype that exists within the vessels) 
A number of vascular smooth muscle mitogens 
whose expression is increased in proliferating vascu- 
lar smooth muscle cells are believed to bind to a 
correspondingly large set of membrane-bound re- 
ceptors, activating a series of intracellular secondary 
messengers, which in turn cause changes in gene 
expression) ,~2 The protein products that result from 
these changes in gene expression are responsible for 
smooth muscle cell behavior. Although it may be 
possible to inhibit the expression of individual mito- 
gens, targeting key intracellular pathways common 
to many or all of these mitogens hould theoretically 
be more successful in reducing or perhaps inhibiting 
smooth muscle cell proliferation. Proto-oncogenes 
are regulators of the cell cycle in that their protein 
products can act as transcription factors, binding to 
and activating the genes controlling cell turn- 
over. 13,14 Interference with the expression of these 
proto-oncogenes should therefore cause a reduction 
in cell proliferation. Antisense and other oligonucle- 
otides, when coincubated with most cell types, are 
unstable because of rapid breakdown by serum 
nucleases) 5 Addition of a phosphorothioate back- 
bone increases tability is without altering binding 
specificity. The antisense is believed to act by binding 
a target sequence of mRNA, thus either inhibiting 
progression and transportation out of the nucleus, 
rendering the mRNA susceptible for destruction by 
RNases, or preventing translation. 16Simons et al. ~7 
have reported a reduction in the development of 
intimal hyperplasia n a model of balloon-injured rat 
carotid artery with an antisense oligonucleotide to 
the proto-oncogene c-myb. By using a gel delivery 
system to deliver the c-myb antisense oligonucleo- 
tides to the outer surface of the balloon-injured ar- 
tery, these investigators educed the development of
infimal hyperplasia to 15% that of control samples. 
The anfisense appeared to work at the level of DNA 
transcription, because these effects were accompa- 
nied by absence of detectable c-myb messenger RNA 
levels in the vascular smooth muscle cells. Villa et 
al.18 in a similar model confirmed the activity and 
uptake of the oligonucleotides and localized the oli- 
gonucleotides to the medial smooth muscle cells 
within 24 hours of encasement. 
Local gel delivery of an antisense oligonucleotide 
would appear to be an ideal treatment for vein bypass 
grafts, because their outer surface, unlike angioplas- 
• tied arteries, is exposed at the time of surgery. The 
thin wall of a venous conduit (two to three smooth 
muscle cell layers in the media) may also be more 
easily penetrated than the outer surface of an arterial 
segment, which has a thick smooth muscle cell layer 
in the media. This study therefore xamines the ef- 
fects of antisense c-myb oligonucleotide with a gel 
delivery system on vein graft intimal hyperplasia and 
vasomotor function, and defines the impact of this 
therapy on endothelial nd smooth muscle cell phe- 
notypes. 
MATERIAL AND METHODS 
Sixty male New Zealand White rabbits weighing 
2.0 to 2.5 kg underwent right common carotid ar- 
tery bypass grafting with reversed ipsilateral external 
jugular vein as previously described) 9 The animals 
were randomized to a control group or one of four 
treatment groups. Seventeen animals had only vein 
graft Surgery performed (control), 14 had their grafts 
coated with 2.5 ml of 30% F 127 Pluronic Gel 
(BASF, Parsiffany, N.J.) alone, 17 animals each had 
their grafts coated with gel containing antisense, and 
6 animals each had their grafts coated with gel con- 
taining one of the other two oligonucleotides (sense 
or nonsense). Two hundred micrograms of each oli- 
gonucleotide was added to 2:5 ml of the gel delivery 
system and was delivered to the outer surface of the 
vein graft after the graft was complete and hemostasis 
was secured. The pluronic gel is reconstituted in
aqueous olution at 4 ° C, at which point it is a liquid. 
On exposure to room temperature (20 ° C) the solu- 
tion immediately forms a gel. After preparation the 
"gel solution" is kept on ice until administered to the 
graft. The gel has beenshown to clear from in vivo 
models in 1 to 2 hours, although oligonucleotide 
activity may be more prolonged. 17 In vitro studies 
have shown that the gel has released 90% of the 
olig0nucleotide by approximately 51 hours, with 
100% release by 67 hours) 8 Three grafts each from 
the control and antisense-treated groups were har- 
vested at 1 day for oligonucleotide uptake/localiza- 
tion analysis and at 3 days for mRNA extraction. The 
remaining rafts were harvested 28 days after sur- 
gery, and the animals were killed with an overdose of 
barbiturates. Animal care complied with the "Princi- 
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pies of Laboratory Animal Care" as formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
issued by the National Institutes of Health (U.S. 
Department of Health and Human Services, NIH 
Publication No. 80-23, revised 1985). 
Oligonucleotides. The oligonucleotides used 
were 18 bases in length and phosphorothioate-stabi- 
lized (Biosynthesis Inc, Lewisville, Tex.). The anti- 
sense used was identical to that used by Simons et 
al. 17 with the sequence GTGTCGGGGTCTC- 
CGGGC (position 4 to 22 of murine antisense). 
Two further oligonucleotides were used: sense GC- 
CCGGAGACCCCGACAC (identical to sequence of 
native myb DNA and complementary to the antisense 
in the 3'-5' direction) and a missense or nonsense 
sequenced comprising the 18 bases of the antisense 
but scrambled in a random fashion, GCCTGGGCT- 
GGCTGGTCG. This last sequence was to control 
for difference in base composition between the com- 
plementary sense and antisense. The rabbit c-myb 
sequence has recently been cloned and was unavail- 
able when these experiments were performed. It dif- 
fers from the murine c-myb y only one base, which 
occurs at position 15 (out of 18). One base pair 
mismatch as been shown not to significantly reduce 
oligonucleotide efficacy, especially when, as in this 
case, the mismatch isnot at the end of the oligonu- 
cleotide. 
Oligonucleotide uptake/localization analysis. 
Fluorescein isothiocyanate-labeled antisense oligo- 
nucleotides were used to coat three vein grafts as 
described previously. Animals were killed after 24 
hours, and the vein grafts were retrieved. Tissue 
localization and uptake were determined by placing 
freshly harvested vein graft segments in 4% para- 
formaldehyde for 3 hours. Specimens were then re- 
moved and cryoprotected in 30% sucrose with 0.1 
mol/L phosphate buffer and frozen at 20 ° C. Frozen 
sections were visualized under fluorescence micros- 
copy. 
Northern analysis. Three control and anti- 
sense-treated 3-day vein grafts were harvested, snap- 
frozen in liquid nitrogen, and stored at -80 ° C until 
use. Total RNA was extracted from the vein grafts 
according to the procedure described by Chomczyn- 
ski and Sacchi, 2° which is a single-step guaninidium- 
phenol-based xtraction method using commercially 
available RNAzol solution (Biotecx, Houston, Tex- 
as). Poly A( + )-enriched mRNA was then purified 
from total RNA with an oligo-dT cellulose batch- 
binding and centrifugation protocol (Micro-Fast- 
Track, Invitrogcn Corp, San Diego, Calif.). For 
Northern blot analysis 5 Ixg mRNA from each sam- 
pie was denatured and fractionated on a 1% agarose/ 
formaldehyde gel and transferred to nylon mem- 
branes by capillary action overnight as previously 
described. 21After transfer the blots were ultraviolet 
(UV) cross-linked and prehybridized at42 ° C for 1 
hour in Rapid-Hyb buffer (Amersham, Clearbrook, 
Ill.). Hybridization was then carried out overnight 
after the end-labeled (with [~/S2p] adenosine triphos- 
phate and T4-Polynucleotide ldnase) antisense c-myb 
oligonucleotide was added. After hybridization was 
performed, blots were washed twice for 20 minutes 
in 55< SSC/0.1% sodium dodecyl sulfate (SDS) at 
room temperature and then in 1× SSC/0.1% SDS 
for 20 minutes at 42 ° C and exposed to x-ray film. 
For c-myb mRNA quantitation the blots were ana- 
lyzed with a PhosphorImager (Molecular Dynamics, 
Sunnyvale, Calif.) to determine specific hybridiza- 
tion. To assess equal RNA loading the e-myb mRNA 
signals were normalized to the control transcript, glyc- 
eraldehyde 3-phosphate dehydrogenase (GAPDH). 
First, c-myb-probed blots were stripped in water at 
100°C for 15 minutes and reprobed with a 32p. 
labeled rat GAPDH cDNA probe. After quantitation 
of the GAPDH signal was performed with a 
Phosphorlmager, the individual c-myb signals were 
normalized with the c-myb/GAPDH signal intensity 
ratio. 
Morphologic studies. After isolation and hepa- 
rinization (200 IU/kg intravenous) 10 grafts each 
from the control, gel, and antisense groups and 6 
each from the sense and nonsense groups were per- 
fusion-fixed in situ at 80 mm Hg as previously de- 
scribed.19 After the graft was immersed in the fixative 
for 48 hours, cross-sections of the mid part of the 
graft were processed and stained with a modified 
Masson's trichrome and VerhoetPs elastin stain. 22 
The lumen, intima, and media were defined and their 
dimensions (area, thickness, or both) calculated by 
videomorphometry (Innovision 150, American In- 
novision Inc., San Diego, Calif.). A ratio of the 
intima and media areas was calculated (intimal ra- 
tio = intimal area/[intimal + medial areas]). A ratio 
of the intimal and medial areas (intimal ratio = inti- 
mal area/[intimal + medial areas]) and a luminal 
diameter to cross-sectional wall thickness (luminal 
index = luminal diameter/[cross-sectional w l
thickness]) was also calculated. For scanning electron 
microscopy mid-portion specimens of the glutaralde- 
hyde-fixed grafts were rinsed with the same buffer 
solution as described previously, dehydrated in as- 
cending concentrations of ethanol, transferred toab- 
solute acetone, critical point-dried from CO2, 
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Fig. 1. A, Composite light photomicrograph s owing 
cross-sections of graft wall from sense-treated, control, and 
antisense-treated groups. /-/, Intimal hyperplasia; M, me- 
dia; boundary between intima and media is indicated by 
arrowheads. 
mounted on specimen stubs, and sputter-coated with 
gold-palladium according to standard techniques. 
All Specimens were examined in a Philips 500 scan- 
ning electron microscope (N.V. Philips, Eindhoven, 
The Netherlands) at an accelerating voltage of 12 or 
20 kV. For transmission electron microscopy repre- 
sentative sections from the midportion of the glutar- 
aldehyde-fixed grafts were postfixed tbr 1 hour at 
room temperature in 1% osmium-tetroxide issolved 
in the same cacodylate buffer as used for the glutaral- 
dehyde solution. After dehydration was performed in 
ascending concentrations of ethanol, the specimens 
were transferred to propylene oxide and finally em- 
bedded in an Epon 812 monomer: Polymerization 
was carried out overnight at 40 ° C followed by 2 
days at 60 ° C. Ultrathin sections were cut with a 
diamond knife on a Reichart ultramicrotome 
(Reichart Optische Werke AG, Vienna, Austria), 
contrasted with uranyl acetate and lead citrate, and 
then examined in a Philips 300 transmission electron 
microscope (N.V. Philips, Eindhoven, The Nether- 
lands), both operated at 60 kV. 
Physiological studies. For isometric tension 
studies four vessels each from the control, gel, and 
gel with antisense groups were sectioned in situ into 
four 5-ram segments and excised, and each ring was 
immediately mounted between two stainless teel 
hooks in 5-ml organ baths containing oxygenated 
Krebs solution (122 mmol /L  NaC1, 4.7 mmol /L  
KC1, 1.2 mmol /L  MgC12, 2.5 mmol /L  CaCI2, 15.4 
mmol /L  NaHCO3, 1.2 mmol /L  KH2PO4, and 5.5 
mmol /L  glucose maintained at 37 ° C and oxygen- 
ated with 95% 0 2 and 5% CO2) as previously de- 
scribed. 19 After equilibration was performed, the 
resting tension was adjusted in increments from 0.5 
to 2.5 gm, and the maximal response to a modified 
oxygenated Krebs solution containing 60 mmol /L  
KC1, 66.7 mmol /L  NaC1, 1.2 mmol /L  MgC12, 2.5 
mmol /L  CaCI2, 15.4 mmol /L  NaHCO3, 1.2 
mmol /L  Iq-I2PO4, and 5.5 mmol /L  glucose was 
measured to establish a length-tension relationship. 
Norepinephrine (10 .9 to l0 -4 mol/L)  was added 
cumulatively in half-molar increments, and the iso- 
metric tension developed by the vessel ring was mea- 
sured as it contracted. After these additions were 
completed, the tissue was allowed to reequilibrate for 
a minimum of 30 minutes until it relaxed to its' 
original resting tension. Cumulative dose response 
curves to bradyldnin (10 -9 to 10 -s mol/L),  hista- 
mine (I0 -9 to 10 -4 mol/L),  and serotonin (10 -9 to 
I0 -4 mol/L)  were then performed in a similar fash- 
ion with reequilibration after each dose response 
curve as before. After precontraction to 75% of max- 
imum with norepinephrine, r laxation in response to 
cumulative doses of acetylcholine (10 .8 to 10 .4 
mol/L)  and sodium nitroprusside (10 .8 to 10 -4 
mol/L)  were also determined. All drugs were ob- 
tained from Sigma Chemical Co. (St Louis, Mo.). 
Data and statistical analysis. The ECs0 value, 
the concentration for the half-maximal response, for 
each agonist in each ring was calculated by logistic 
analysis and is expressed as the pD2, which is defined 
as -logl0[ECs0]. 23 Emax (the maximal response x- 
pressed as a ratio of the contraction to 60 mmol /L  
KCI) was also calculated. All data are presented as the 
mean _ SEM, and statistical differences among 
groups were tested by analysis of variance (ANOVA) 
with post hoc Tukey-Kramer multiple comparison 
tests for the functional studies and with a I(a'uskal- 
Wallis nonparametric ANOVA with post hoc Dunn's 
multiple comparison tests for the morphometric data. 
A p value less than 0.05 was regarded as significant. 
RESULTS 
Morphologic characteristics. All animals sur- 
vived to harvest, and all grafts were patent at harvest. 
On microscopic evaluation the luminal surfaces of 
the vein grafts from all five groups were covered by a 
layer of intact endothelial cells, bencath which lay a 
hyperplastic ntima with the smooth muscle cells of 
the intimal hyperplasia rranged in a crisscross pat- 
tern with little extracellular matrix between (Fig. 1). 
The medial smooth muscle cells in the grafts from all 
five groups appeared slender, were arranged in a 
circular pattern, and contained a greater amount of 
extracellular matrix suggestive of medial hypertro- 
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Table I. Dimensional analysis 
Antisense 
Control Pluronic gel e-myb Sense c-myb Nonsense c-myb p 
Intimal thickness (brm) 70 + 4 72 + 4 44 - 6{# 65 2_ 5 68 ± 9 0.01 
Medial thickness (Ixm) 65 + 5 58 ± 6 65 ± 16 76 + 4 64 ± 8 0.53 
Luminal area (mm 2) 20.5 _+ 1.5 26.9 ± 2.8 21.3 ± 4.3 24.0 + 1.9 31.2 + 6.9 0.13 
Intimal area (mm 2) 1.14 _+ 0.09 1.32 ± 0.12 0.57 _+ 0.09§[I 1.11 ± 0.12 0.98 - 0.30 0.01 
Medial area (mm 2) 1.08 ± 0.11 1.08 _+ 0.12 1.01 ± 0.28 1.36 ± 0.06 1.30 - 0.25 0.41 
Intimal ratio 0.52 ± 0.02 0.55 ± 0.03 0.38 ± O.043g 0.45 ± 0.02 0.49 - 0.07 0.03 
Luminal index 39.4 _+ 2.6 44.1 ± 2.9 44.1 ± 4.4 43.5 _+_ 3.8 47.0 + 5.3 0.39 
Intimal and medial dimensions from the mid-section of  grafts from the five experimental groups. The data are expressed as the mean -+ 
SEM of the thickness (microns) and area (mm 2) for the intima and the media of the vessels from each group. Intimal ratio = intimal 
area/intimal + medial areas. Luminal index = luminal diameter/Cross-sectional wal thiclmess. 
p < 0.05 considered as significant (Kruskal-Wallis nonparametric test with Dunn's  post hoc analysis). 
*p < 0.01 antisense versus control/gel alone. 
tP < 0.01 antisense versus control/gel alone. 
{p < 0.01 antisense versus ense/nonsense. 
§p < 0.01 antisense versus control/gel alone. 
1~ = 0.05 antisense versus ense/nonsense. 
phy. Dimensional analysis of the control and treatcd 
groups is shown in Table I. There was a 38% reduc- 
tion in vein graft intimal thiclmess when the anti- 
sense/gel group was compared with both the control 
and gel alone groups (p < 0.01), On comparing 
intimal areas the antisense group was the only group 
in which there was a significant reduction (50%) 
compared with thc control group (p < 0.0i). These 
reductions were not seen with the other oligonuclc- 
otidcs. There was no significant difference in either 
medial thickness or area when all groups were com- 
pared. The intimal ratio was reduced to significance 
in the antiscnse gel group only when compared with 
the control group (p > 0.03). Because one can argue 
that the true singlc control for the gcl/antiscnse is 
the gel with sensc or nonsense oligonuclcotide 
present, a secondary analysis of the data was per- 
formed that confirmed the findings of the primary 
data analysis. The intimal thickness was reduced (p < 
0.01) without a change in medial thickness. The 
intimal ratio was decreased but failed to reach statis- 
tical significancc (p = 0.06, Table I). 
Scanning electron microscopy ofthc vascular sur- 
face of grafts from all groups showed that all grafts 
were covered by an uninterrupted layer of endothc- 
lial cells with well-defined borders. The endothelial 
cells of the control vein graft were characterized by 
their spindle-shaped outlines and numerous urface 
microprojections (Fig. 2, A). In contrast, all the 
gel-treated grafts (with and without oligonucleo- 
tides) reveal a polygonal outline with almost com- 
plete absence of the surface microprojections (Fig. 2, 
B and C). The corresponding transmission electron 
micrographs confirmed the presence of an intact en- 
dothelial monolayer on the luminal surface of all 
grafts examined. All the vein grafts in this study 
showed evidence of both contractile and synthetic 
Smooth muscle cell phenotypes within their vessel 
walls. The subendothelium of the control vein graft 
was characterized by numerous layers of smooth- 
muscle cells lying on a well-organized connective 
tissue matrix (Fig. 3, A). There was a predominance 
of contractile phenotypes in control grafts and syn- 
thetic phenotypes in all the treated grafts; these 
smooth muscle cells were predominantly of the con- 
tractile phenotype, having well-defined bundles of 
contractile material peripherally located within the 
cytoplasm. The subendothelium of grafts from the 
other four groups revealed a similar architecture; 
however, most smooth muscle cells were of the syn- 
thetic phenotype (cytoplasm containing a large 
amount of synthetic organelles) (Fig. 3, B and C). 
The connective tissue of the intercellular spaces dis- 
played a more chaotic pattern than did that of the 
control grafts. 
Physiological studies. Vein grafts from the con- 
trol, gel, and antisense groups responded in a con- 
centration-dependent manner to norepinephrine, 
histamine, bradyldnin, and serotonin without a sig-- 
nificant change in their respective sensitivities (Table 
II). The Emax for the vessels in the antisense group 
was unchanged for norepinephrine, histamine, and 
serotonin (Table II) but was decreased for bradyki- 
nin when compared with the control group (0.39 -+ 
0.05 vs 0.84 + 0.08;/9 < 0.05). Precontracted vein 
grafts from the control group did not respond to 
ace@choline; however, 16 (67%) of the 24 graft: 
rings from the gel-only group did respond to ace@- 
choline, relaxing to 59% + 7% ofprecontracted ten- 
sion. In contrast to both the control and gel-treated 
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Fig. 2. A, Scanning electron micrograph of endothelial surface of control vein graft showing 
endothelial cells' well-defined cell borders (a rowhead), spindle-shaped outlines, and numerous 
minute surface processes (white dots). B, Scanning electron micrograph of graft treated with 
pluronic gel containing sense c-myb oligonucleofide. Endothelial cells have sharp borders but 
unlike control grafts reveal more rounded polygonal outline. There are markedly less minute 
surface processes than in A. C, Scanning electron micrograph of graft reated with pluronic gel 
containing anfisense c-myb oligonucleofide. Findings aresimilar to those in B; however, 
endothelial cells in these grafts have surface areas approximately ne-third arger. 
vein grafts, all rings from the antisense group re- 
sponded to acetylcholine, relaxing to 58% ± 9% of 
precontraction (Table II). Grafts from all three 
groups responded in a concentration-dependent 
manner to sodium nitroprusside after precontracfion 
without any difference in sensitivity between groups 
(Table II). 
Oligonucleotide uptake/localization a alysis. 
Fluorescein isothiocyanate-labeled antisense oligo- 
nucleotides were uniformly distributed within the 
media and adventitia by 1 day (Fig. 4). 
Northern blot analysis. Analysis of RNA from 
control and c-myb antisense-treated vein grafts har- 
vested at 3 days showed no significant difference in 
c-myb mRNA expression between the two groups 
(Fig. 5). 
DISCUSSION 
Vascular smooth muscle cell mitogens are be- 
lieved to bind membrane-bound receptors, trigger- 
ing the activation of secondary messenger systems. 
These different cytosolic signals converge through 
activation and production of protein transcription 
factors, which in turn bind the DNA of genes that 
regulate the cell cycle, causing replication and cell 
division.15 Biochemically active nuclear oncoproteins 
such as myb act as transcription factors, c-myb is a 
proto-oncogene that was originally thought present 
only in hemopoietic cells, 13 but it is now known to 
be present and to regulate the cell cycle in many cell 
types including vascular smooth muscle cells. 15 The 
myb protein is a sequence-specific DNA binding 
protein that binds to and activates promoter se- 
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Fig. 3. A, Transmission electron micrograph of control vein graft. Luminal surface shows 
monolayer of well-defined endothelial cells, with minute surface processes at cell borders and on 
cell surface proper (arrowheads). Subendothelium contains multiple layers of smooth muscle 
cells predominantly ofcontractile phenotype (i.e., cytoplasm containing abundant contractile 
elements) embedded in matrix containing ill-defined connective tissue (*). B, Transmission 
electron micrograph of graft reated with pluronic gel containing sense c-myb oligonucleotide. 
Beneath intact endothelium there is similar architecture to control grafts; however, most 
smooth muscle cells are of synthetic phenotype (i.e., cytoplasm contains large number of 
synthetic organelles). Connective tissue of intercellular spaces (*) display more chaotic pattern 
than that of control grafts. C, Transmission electron micrograph of graft treated with pluronic 
gel containing antisense c-myb oligonucleotide. Findings are similar to B with intact endothelial 
cell monolayer and subendothelium containing smooth muscle cells ofpredominantly s nthetic 
phenotype. 
quences on genes with the appropriate binding site 
and results in cell growth and proliferation. 13c-myb 
expression i creases from low baseline levels in qui- 
escent cells to peak level when cells enter the late G 1 
phase of the cell cycle. In proliferating cells, where 
the cell cycle moves directly from the G 1 phase to the 
S phase, peak levels occur at this G1/S interface, is
Simons et al. 24 demonstrated that antisense c-myb 
oligonucleotide, when administered to cultured rat 
vascular smooth muscle cells, caused a reduction in 
cell proliferation of  approximately 50% and that 4 
hours of incubation with antisense produced the 
same degree ofantiproliferative activity as incubation 
for 72 hours. There was a marked reduction in c-myb 
messenger RNA levels, with levels approximately 
25% that of cells incubated with sense c- myb oligonu- 
cleotide. Application of  the antisense oligonucleo- 
tide to the external surface of a balloon-injured rat 
carotid artery with a gel delivery system produced 
similar resultsJ 7 Intimal thickness was reduced to 
15% of sense control levels, with c-myb messenger 
RNA levels considerably reduced. Our results also 
showed a significant effect with a total 38% reduction 
in intimal thiclmess without producing changes in 
the dimensions of  the media. 
The antiproliferative effects of antisense oligonu-- 
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Table II. Sensitivity of physiologic responses 
Control Gel Antisense 
Agonist vein graft vein graft vein graft p 
Contraction Norepinephrine 6.00 ± 0.08 6.04 ± 0.06 6.12 ± 0.10 NS 
Histamine 5.05 +_ 0.04 4.92 ± 0.05 5.09 ± 0.11 NS 
Bradykinin 5.47 + 0.05 5.72 ± 0.06 5.50 ± 0.09 NS 
Serotonin 6.34 ± 0.09 6.06 ± 0.07 6.08 ± 0.06 NS 
Relaxation Acetylcholine No response 7.25 ± 0.41" 6.02 -+ 0.16"~ <0.01 
Sodium nitroprusside 6.04 ± 0.08 6.11 ± 0.17 6.15 _+ 0.15 NS 
Sensitivity of vein grafts from control, gel, and antisense-treated grafts to both contractile and relaxing agonists. 
The data are expressed as the mean ± SEM of the pD2, ( - log  ECs0 ) with statistical nalyses by ANOVA with Tukey-Kramer post hoc test. 
* 16 out of 24 tings responded. 
tall rings responded. 
Table II I .  Maximum physiologic responses 
Control Gel Antisense 
Agonist vein graft vein graft vein graft p 
Norepinephrine 1,25 +- 0.07 1.23 ± 0.11 1.49 ± 0.14 NS 
Histamine 0,94 ± 0.10 0.65 ± 0.06 1.09 ± 0.15 NS 
Bradyldnin 0.84 ± 0.08 0.68 ± 0.10 0.39 ± 0.05* <0.05 
Serotonin 0.87 +- 0.11 0.77 ± 0.13 0.49 ± 0.07 NS 
Emax (the maximal response xpressed as a ratio of the contraction to 60 mmol /L  KCI) of  vein grafts from control, gel, and 
anfisense-treated grafts. The data are expressed as the mean _ SEM with statistical nalyses by ANOVA with Tukey-Kramer post hoc test. 
*p < 0.05 compared with control. 
cleotides have been attributed to direct inhibition of 
the mRNA of the relevant gene under investigation; 
however, the mechanism of action ofantisense 'oligo- 
nucleotides on cellular proliferation has recently 
come into question. 18,2~ Antisense oligonucleotides 
to the proto-oncogenes c-myb and c-myc have been 
shown to have a sequence of four consecutive 
guanosine (G) residues as part of their base con- 
struct. Other oligonucleotides containing this 4G 
sequence have been shown to have the same antipro- 
liferative ffect in smooth muscle cells in vitro. Bur- 
gess et al., 2s with growth-arrested cultured vascular 
smooth muscle cells, showed that the percentage of 
cells entering the S phase of the cell cycle is reduced 
when 4G base sequences are compared with non-4G 
sequences irrespective of whether the sequence is an 
antisense sequence. The "4G" effect does not, how- 
ever, explain the ability of antisense technologies to 
inhibit smooth muscle cell proliferation in some in 
vivo studies. Villa et al.,~8 although showing a reduc- 
tion in vascular smooth muscle cell proliferation in 
vitro with 4G sequences, failed to show any reduc- 
tion on the development of intimal hypcrplasia in a 
model of balloon-injured rat common carotid artery 
with antisense and random sequence oligonucleo- 
tides containing 4G sequences when compared with 
the result obtained with a sense oligonucleotide that 
did not have a 4G sequence. In addition, Mann et 
al.26 have shown a clear reduction in experimental 
vein graft intimal hyperplasia with liposome-aided 
uptake of antisense to proliferating cell nuclear anti- 
gen and cell division cycle 2 kinase (cdc2 kinase), 
neither of which contain a 4G sequence. More re- 
cendy, pluronic gel delivered antisense oligonucleo- 
tide to proliferating cell nuclear antigen, which lacks 
a 4G sequence, has been shown to be effective in 
reducing intimal hyperplasia. 27The cumulative im- 
pact of these data suggest that the 4G theory cannot 
reasonably explain the findings reported in this study. 
In this study c-myb fluorescent oligonucleotides 
were evenly distributed throughout the media and 
adventitia of the vein within 24 hours, confirming 
earlier work by Villa et al) s c-myb mRNA was de- 
tected in all oligonucleotide grafts at 3 days; how- 
ever, we could not demonstrate a decrease in the 
antisense-treated grafts. The presence of detectable 
c-myb expression suggests that there is a continued 
stimulus to smooth muscle cell proliferation. This 
finding would suggest that the single application of 
antiscnse may not be sufficient o fully control the 
proliferative response. This weakness of antisense 
technology has recently been highlightedY Alterna- 
tively, the dosage ofantisense chosen, although iden- 
tical to that used to inhibit smooth muscle cell pro- 
JOURNAL OF VASCULAR SURGERY 
Volume 25, Number 3 Fulton et aL 461 
Fig. 4. Paired phase contrast (A) and fluorescence photomicrographs (B) of 1-day vein graft 
that has been coated in fluorescenfly labeled antisense c-myb oligonucleotide within pluronic 
gel. Fluorescent oligonucleotide can be identified within media ( rrow). 1, Lumen; m, media; a, 
adventitia. 
liferation in the rat restenosis model, may not have 
been sufficient o completely inhibit the production 
of c- myb mRNA in the vein graft. Although mRNA 
levels in the antisense-treated grafts are unchanged 
from control evels, it is also possible that the mRNA 
may be antisense-bound and therefore detectable but 
nonfunctional. Finally, veins are exposed to very dif- 
ferent hemodynamics on grafting into the arterial 
circulation, malting models of vein graft intimal hy- 
perplasia different from balloon-injured arterial mod- 
els. Vein grafts undergo continued remodeling as a 
result of the their continued exposure to a new he- 
modynamic environment. 29 This continued expo- 
sure partly explains the universal response of intimal 
hyperplasia in all veins after vein grafting. Antisense 
technology to inhibit intimal hyperplasia in vein 
grafts may lead to a different response than that 
obtained in balloon-injured arteries, which remain in 
their native circulation and neither experience a new 
and continued hemodynamic environment or the 
trauma of harvest and implantation. 3°
The use of pluronic gel did not change graft 
dimensions when used in the non-antisense groups 
compared with the control group. There was, how- 
ever, alteration in the ultrastructure of the grafts in all 
four groups treated with gel. All the vein grafts in this 
study showed evidence of  both contractile and syn- 
thetic smooth muscle cell phenotypes within their 
vessel walls. A predominance of contractile pheno- 
types in control grafts and synthetic phenotypes was 
seen in all the treated grafts. These changes were also 
associated with a difference in the morphologic har- 
acteristics and the responsiveness of the overlying 
1 2 3 4  
Hg. 5. Representative Northern blot analysis of c-myb 
mRNA from 3-day control (lanes 1 and 2) and 3-day 
antisense oligonucleotide-treated (lanes 3 and 4) vein 
grafts. Messenger RNA was isolated from frozen samples, 
and approximately 5 ~g was electrophoresed, blotted, and 
hybridized with 32p-labeled c-myb antisense oligonucleo- 
tide as described in Methods. Specific hybridization to 
approximate 4kb c-myb mRNA was quantitated with a 
Phosphorlmager (Molecular Dynamics, Sunnyvale, Calif.) 
and normalized to specific hybridization of GAPDH 
mRNA following c- myb probe removal (Methods, data not 
shown). No significant differences in c-myb mRNA levels in 
3-day antisense-treated vein grafts were observed. 
endothelial cells. Predominance of smooth muscle 
cells with a contractile phenotype is consistent with 
our result to date on the smooth muscle cell mor- 
phologic haracteristics in the control vein graft at 28 
days and has been found to reflect a steady mature 
state of the vein graft and its associated intimal hy- 
perplasia. The presence of  a predominance ofsmooth 
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muscle cells with a synthetic phenotype in the treated 
grafts is a common finding in any morphologic study 
of vein grafts that have been treated with a com- 
pound that has had an effect in reducing intimal 
hyperplasia. The presence of synthetic smooth mus- 
cle cells in the vein grafts would suggest that the vein 
graft is not in a steady state and may indicate either 
that there is still some ongoing smooth muscle pro- 
liferation or that the maturation process has been 
altered in these grafts, which in itself may contribute 
to the decrease in intimal" hyperplasia present. Irre- 
spective of the changes in ultrastructural morpho- 
logic characteristics the vein graft smooth muscle 
cells did not show changes in their phenotype (i.e., 
there was no change in the response to the panel of 
contractile agents used). 
Although vein grafts in the rabbit remain physio- 
logically responsive conduits, acetylcholinc-mediated 
relaxation is lost after grafting, reflecting altered en- 
dothelial cell function. The preservation of receptor- 
mediated endothelium-dependent r laxation in each 
of the vein grafts is associated with a difference in the 
morphologic haracteristics of the intimal surface 
observed on scanning electron microscopy. It is likely 
that the effects reflect two processes: one that is 
related to the pluronic gel (67% of specimens re- 
laxed) and the second related to the present of the 
antisense oligonucleotides (100% of specimens re- 
laxed). The effect of the pluronic gel-treated groups 
in preserving a degree of  acetylcholine-mediated re- 
laxation is unclear. The surfactant-based polymer 
may have some cell-protective effects caused by stabi- 
lization of the cell membranes. In addition, as a 
polyglycol the gel may confer some as yet uncharac- 
terized antioxidant effects, which may reduce free 
radical formation, aprocess that is known to improve 
vein graft function in vein grafts. 31 The further pres- 
ervation ofvasorelaxant response when the antisense 
oligonucleotide is added is unique and is not fully 
explicable given the known characteristics of the oli- 
gonucleotides. The degree of intimal hyperplasia re- 
duction may partly contribute to  this response, but a 
similar reduction in intimal hyperplasia has not been 
associated with similar preservation ofvasorelaxant 
response. In contrast to the changes in endothelial 
cell function, the response of the smooth muscle 
cells to a panel of contractile agonists was un- 
changed by either the presence of  the gel alone or 
with added antisense. This absence of  change oc- 
curred despite the decrease in the degree ofintimal 
hyperplasia nd the apparent increase in the num- 
ber of  smooth muscle cells with synthetic pheno- 
types. 
CONCLUSIONS 
Locally delivered antisense oligonucleotides to 
proto-oncogene c-myb significantly reduces intimal 
hyperplasia with preservation of acetylcholine-medi- 
ated endothelium-dependent relaxation in experi- 
mental vein grafts. These findings suggests that tar- 
geting a common regulatory pathway of vascular 
smooth muscle mitogenesis can be successful in re- 
ducing the early development ofintimal hyperplasia. 
Pluronic gel can be used successfully as an oligonu- 
cleotide delivery system and may be particularly 
suited to vein grafts, because vein bypass grafting 
always allows access to the outer surface. The gel, 
with successful agent delivery and ease of application, 
may have major potential in the clinical setting. 
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